MicroRNA Expression in Lung Cancer Development and Progression
MicroRNA Expression in Lung Cancer Development and Progression
批准号:
7873350
负责人:
SERGE PATRICK NANASINKAM
金额:
$16.58万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2010
资助国家:
美国
项目状态:
已结题
起止时间:
2010-02-05 至 2012-01-31
关键词:
AdenocarcinomaAnimalsApoptosis Regulation GeneBiologicalCancer EtiologyCancer PatientCell Differentiation processCessation of lifeCountryDevelopmentDiseaseEarly DiagnosisEpidermal Growth FactorErlotinibExhibitsFamilyFunctional RNAGefitinibGene ExpressionGene Expression RegulationGene ProteinsGenesGenomeGrowthHematopoieticHeterogeneityIn VitroLabelLungLung NeoplasmsMaintenanceMalignant NeoplasmsMalignant neoplasm of lungMessenger RNAMicroRNAsModelingMolecularMorphologyMusMutationNon-Small-Cell Lung CarcinomaOncogenesOrganismPathway interactionsPatternPlant VirusesProtein AnalysisProteinsResearchResistanceScreening procedureSecondary toSignal TransductionSmokerSolidSubgroupTobacco Use CessationTransgenic ModelTranslationsTumor Suppressor ProteinsWomanchemotherapeutic agenthigh riskinhibitor/antagonistlung tumorigenesismRNA Transcript Degradationmenmortalitynovelprogramspublic health relevanceresponsetumortumor initiationtumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Lung cancer is the most frequent cause of cancer deaths in this country for both men and women. In 2009, 236,000 new cases and 163,000 deaths are estimated. The overall five year mortality has changed very little in the last two decades. Lung cancer represents a group of heterogeneous diseases that despite similar morphology exhibit different growth rates, metastatic potential and response to therapies. New targeted therapies such as epidermal growth factor inhibitors (EGFR) (Erlotinib and Gefitinib) have been successful in distinct subgroups of lung cancer patients. K-Ras exists downstream from EGFR signaling and approximately 30% of non-small cell lung cancers (adenocarcinomas) harbor K-Ras activation secondary to mutations. EGFR and K-Ras mutations represent very distinct subgroups of lung cancers with differing patterns of sensitivity and resistance to chemotherapeutic agents as well as potential differences in survival. K-Ras mutations tend to occur in former or active smokers while EGFR mutations are more common in never smokers. MicroRNAs (miRNAs) are a family of endogenous, small non-coding RNAs (approximately 21-25 nt long) expressed in many organisms. MiRNAs represent a newly discovered layer of gene regulation by targeting mRNA for degradation or inhibition of translation. A single miRNA may target several hundreds of genes. MiRNAs are integral to gene regulation, apoptosis, hematopoietic development, the maintenance of cell differentiation and may function as either tumor suppressors or oncogenes. We propose that a multi-platform approach that incorporates microRNA expression and target protein analysis both early and late in K-Ras related tumorigenesis as well as during regression will identify select miRNAs, critical biological pathways and potential targets for early diagnosis and treatment of lung cancer. We have two specific aims to our proposal: Specific Aim 1: Use a conditional murine model of K-Ras induction to define longitudinal patterns of miRNA expression that occur during tumor initiation, progression, establishment and regression and Specific Aim 2. Through the use of high throughput gene expression integrate miRNA and mRNA patterns of expression to identify key miRNA/target relationships and biological pathways that are relevant to K-Ras lung tumorigenesis
PUBLIC HEALTH RELEVANCE: Lung cancer is the most frequent cause of cancer deaths in this country for both men and women. In 2009, 236,000 new cases and 163,000 deaths are estimated. This has resulted in tremendous societal and financial burden. Therefore, in addition to aggressive programs for tobacco cessation and more efficacious means of early detection, novel molecular approaches to understanding disease heterogeneity such as microRNA profiling will be important in our battle against this deadly disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
CTSA K12 Program at Virginia Commonwealth University
-
批准号:10619075
-
项目类别:
-
资助金额:$74.95万
-
财政年份:2023
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
Project 1: Lung Cancer
-
批准号:10493289
-
项目类别:
-
资助金额:$13.29万
-
财政年份:2021
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
Project 1: Lung Cancer
-
批准号:10290161
-
项目类别:
-
资助金额:$14.87万
-
财政年份:2021
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
Institutional Career Development Core
-
批准号:10409658
-
项目类别:
-
资助金额:$74.29万
-
财政年份:2018
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
Institutional Career Development Core
-
批准号:9913602
-
项目类别:
-
资助金额:$74.29万
-
财政年份:2018
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
MicroRNA Expression in Lung Cancer Development and Progression
-
批准号:8021770
-
项目类别:
-
资助金额:$19.3万
-
财政年份:2010
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
Integration of transcriptosome and microRNome in Understanding COPD Phenotypes
-
批准号:7690864
-
项目类别:
-
资助金额:$7.5万
-
财政年份:2008
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
Regulation of Prostacyclin in Pulmonary Hypertension
-
批准号:6817114
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2004
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
Regulation of Prostacyclin in Pulmonary Hypertension
-
批准号:7480211
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2004
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
Regulation of Prostacyclin in Pulmonary Hypertension
-
批准号:6933068
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2004
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
Regulation of Prostacyclin in Pulmonary Hypertension
-
批准号:7106518
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2004
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
Regulation of Prostacyclin in Pulmonary Hypertension
-
批准号:7283716
-
项目类别:
-
资助金额:$13.15万
-
财政年份:2004
-
负责人:SERGE PATRICK NANASINKAM
-
依托单位:
海外基金